Profil Klinis Pasien Pengguna Warfarin Pada Poli Jantung RSUD Dr. Soeselo Kabupaten Tegal

https://doi.org/10.22146/farmaseutik.v1i1.62470

Fita Rahmawati(1*), Ismi Arsyi Arsyi Aulia(2), I Dewa Putu Pramantara(3)

(1) Departemen Farmakologi dan Farmasi Klinik Universitas Gadjah Mada
(2) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) 3SMF Geriatri, RSUP Dr. Sardjito
(*) Corresponding Author

Abstract


Warfarin merupakan antikoagulan oral yang biasa diresepkan untuk mencegah dan mengobati kejadian tromboemboli. Warfarin memiliki jendela terapi yang sempit, variabilitas luas dalam dosis-respons antar individu, dan sejumlah besar interaksi terhadap obat dan makanan. Penelitian ini bertujuan mengetahui profil klinis pasien pengguna warfarin pada Poli Jantung RSUD dr Soeselo Kabupaten Tegal. Penelitian ini merupakan penelitian descriptive cross sectional. Pengambilan data dilakukan secara prospektif menggunakan tehnik consecutive sampling pada bulan 15 Juni – 6 Agustus 2020 di Poli Jantung RSUD  dr.Soeselo Kabupaten Tegal. Sejumlah 97 pasien memenuhi kriteria inklusi dalam penelitian ini. Profil klinis pasien yang menggunakan warfarin diperoleh melalui penelusuran rekam medik dan wawancara terstruktur.  Analisis data dilakukan secara deskriptif. Hasil penelitian mendapatkan rerata usia pasien 53,5 tahun dengan usia paling banyak pada rentang 60-80 tahun (38%). Proporsi perempuan lebih banyak (70%) dengan mayoritas tingkat pendidikan pada level tingkat dasar (66%). Indikasi terbanyak penggunaan warfarin adalah Atrial Fibrilasi (91%) dengan durasi penggunaan warfarin paling banyak pada rentang waktu hingga 6 bulan (36%) diikuti penggunaan warfarin lebih dari 25 bulan (31%). Pada penelitian ini International Normalized Ratio (INR) yang mencapai rentang terapeutik hanya sebesar 11%, sedangkan efek samping obat terjadi pada 10% pengguna warfarin.  Informasi gambaran profil penggunaan warfarin sangat diperlukan untuk menentukan strategi lebih lanjut dalam upaya meningkatkan luaran terapi pasien. 


Keywords


warfarin; profil klinis; International Normalized Ratio; efek samping

Full Text:

PDF


References

Abdou, J..K., Auyeung, V., Patel, J.P., dan Arya, R., 2016. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. John Wiley & Sons Ltd. British Journal of Haematology, 2016, 174, 30–42.

Absher, R.K., Moore, M.E., dan Parker, M.H., 2002. Patient-Specific Factors Predictive of Warfarin Dosage Requirements. The Annals of Pharmacotherapy, 6.

Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., dan Palareti, G., 2012. Oral Anticoagulant Therapy. Chest, 141: e44S-e88S.

Al-Momany, N.H., Makahleh, Z.M., Al-Omari, N.A., Al-Sarayreh, H.A., dan Momani, R.O., 2019. Analysis of Factors That Interrupt With INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients. Clinical and Applied Thrombosis/Hemostasis, 25: 107602961987025.

Capodanno, D. dan Angiolillo, D.J., 2010. Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology, 56: 1683–1692.

Cavallari, L.H., Shin, J., dan Perera, M.A., 2011. Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants. Pharmacotherapy, 31: 1192–1207.

Choi, K.H., Kim, A.J., Son, I.J., Kim, K.-H., Kim, K.-B., Ahn, H., dkk., 2010. Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting. Journal of Korean Medical Science, 25: 337.

Dahal, K., Kunwar, S., Rijal, J., Schulman, P., dan Lee, J., 2016. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease. Chest, 149: 951–959.

Davis, N.J., Billett, H.H., Cohen, H.W., dan Arnsten, J.H., 2005. Impact of Adherence, Knowledge, and Quality of Life on Anticoagulation Control. Annals of Pharmacotherapy, 39: 632–636.

Furdiyanti, N.H., Pramantara, I.D.P., dan Wahyono, D., 2014. Evaluasi Dosis Warfarin dan Hasil Terapinya pada Pasien Rawat Jalan. Jurnal Manajemen dan Pelayanan Farmasi, 4: 5.

Hawes, E., 2018. Patient Education on Oral Anticoagulation. Pharmacy, 6: 34.

Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., dkk., 2020. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal, ehaa612.

Hirsh, J., Fuster, V., Ansell, J., dan Halperin, J.L., 2003. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 107: 1692–1711.

Holbrook, A.M., 2005. Systematic Overview of Warfarin and Its Drug and Food Interactions. Archives of Internal Medicine, 165: 1095.

Howard-Thompson, A., Luckey, A., George, C., Choby, B.A., dan Self, T.H., 2014. Graves’ Disease and Treatment Effects on Warfarin Anticoagulation. Case Reports in Medicine, 2014: 1–6.

ISTH Steering Committee for World Thrombosis Day, 2014. Thrombosis: a major contributor to the global disease burden. Journal of Thrombosis and Haemostasis, 12: 1580–1590.

Jacobs, L.G., 2008. Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly. Cardiology Clinics, , Thromboembolic Disease and Antithrombotic Agents in the Elderly 26: 157–167.

Katzung, B.G. dan Zehnder, J.L., 2012. Drugs Used In Disorders of Coagulation, Dalam Basic & Clinical Pharmacology, 12th ed. McGraw-Hill Medical, New York.

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., dkk., 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50: e1–e88.

Klotz, U., 2009. Pharmacokinetics and drug metabolism in the elderly. Drug Metabolism Reviews, 41: 67–76.

Lemeshow, S., Hosmer, D.W., Klar, J. and Lwanga, S.K. 1990.Adequacy of Sample Size in Health Studies. John Wiley & Sons,New York.

Nathisuwan, S., Dilokthornsakul, P., Chaiyakunapruk, N., Morarai, T., Yodting, T., dan Piriyachananusorn, N., 2011. Assessing Evidence of Interaction Between Smoking and Warfarin. Chest, 139: 1130–1139.

Ng, K.P., Edwards, N.C., Lip, G.Y.H., Townend, J.N., dan Ferro, C.J., 2013. Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. American Journal of Kidney Diseases, 62: 615–632.

Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., dkk., 2004a. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ : British Medical Journal, 329: 15–19.

Perk, J., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., Albus, C., dkk., 2012. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 33: 1635–1701.

PERKI, P., 2019. Pedoman Tata Laksana Fibrilasi Atrium Non Valvular. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, 156.

Pertiwi, D., Suwarso, E., dan Manik, P., 2017. Evaluasi Penggunaan Warfarin Oral Dengan Penentuan Frekuensi Pemeriksaan Dan Nilai International Normalized Ratio (INR) Pada Pasien Jantung Di Pusat Jantung Terpadu RSUP H. Adam Malik; Universitas Sumatera Utara.

Putriana, N.A., Lestari, K., Barliana, M.I., dan Hartini, S., 2017. Effects of Pharmacist Counseling on Complience and INR Score on Outpatients Receiving Warfarin at DR. Hasan Sadikin Bandung Hospital West Java, Indonesia. Asian Journal of Pharmaceutical and Clinical Research, 10: 72.

Rowland, M. dan Tozer, T.N., 2011. Clinical Pharmacokinetics and Pharmacodynaics: Concepts and Aplications, 4th Ed, 4th ed. Wolter Kluwer Health/Lipincott William & Wilkins, Philadelpia.

Schultz, W.M., Kelli, H.M., Lisko, J.C., Varghese, T., Shen, J., Sandesara, P., dkk., 2018. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation, 137: 2166–2178.

Schwarz, U.I. dan Stein, C.M., 2006. Genetic Determinants of Dose and Clinical Outcomes in Patients Receiving Oral Anticoagulants. CLINICAL PHARMACOLOGY & THERAPEUTICS.

Sheikh-Taha, M. dan Khoury, G., 2014. Effect of age and sex on warfarin dosing. Clinical Pharmacology: Advances and Applications, 103.

Sonuga, B.O., Hellenberg, D.A., Cupido, C.S., dan Jaeger, C., 2016. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. African Journal of Primary Health Care & Family Medicine, 8: .

Tang, E.O.Y., Lai, C.S., Lee, K.K., Wong, R.S., Cheng, G., dan Chan, T.Y., 2003. Relationship Between Patients’ Warfarin Knowledge and Anticoagulation Control. Annals of Pharmacotherapy, 37: 34–39.

Walling, A.D., 2000. Concurrent Disease Alters Warfarin Effectiveness. Am Fam Physician, .

Yamagishi, S., 2019. Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. Cardiovascular Diabetology, 18: 12, s12933-019-0818–0.

Zagozdzon, P., Parszuto, J., Wrotkowska, M., dan Dydjow-Bendek, D., 2014. Effect of unemployment on cardiovascular risk factors and mental health. Occupational Medicine, 64: 436–441.



DOI: https://doi.org/10.22146/farmaseutik.v1i1.62470

Article Metrics

Abstract views : 573 | views : 305

Refbacks

  • There are currently no refbacks.


Majalah Farmaseutik Indexed by:

   
 
 
Creative Commons License